Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

COMPLETED

NCT04065048

A Dietary Intervention Study on the Microbiome in Crohn's Disease Patients

Sponsor: Case Western Reserve University

View on ClinicalTrials.gov

Summary

This protocol is designed to compare the effectiveness of a soy-based diet or identical diet without soy given to patients with Crohn's disease (CD) in remission, patients with active CD, or healthy controls. The assigned diet will be compared to participant 'baseline' (pre-diet) in terms of its ability to change the gut bacteria and fecal butyrate, an important short-chain fatty acid (SCFA) that limits bowel inflammation, a characteristic of this debilitating disease.

Official title: A Single-center Open-label Study to Determine the Effect of Diet on Microbiome Signatures in Crohn's Disease Patients

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2019-11-01

Completion Date

2023-10-10

Last Updated

2026-06-03

Healthy Volunteers

Conditions

Crohn Disease

Interventions

OTHER

Soy based diet

The diet will be based on the detailed descriptions according to the American Heart Association, US Food and Drug Administration (FDA), and the Soyfoods Association of North America Website, which all promote soy products as having beneficial nutrient profiles with a daily consumption of 25 grams or more of soy protein (average serving = 6.25 grams), upper limit of 50g.

OTHER

Non-soy based diet

Diet of identical composition to the soy diet with the exception of soy.

Inclusion Criteria: * CD subjects: Documented diagnosis of Crohn's disease. Control subjects: no documented diagnosis of CD. * CD subjects: Harvey Bradshaw Index (HBI) score \<4 ('CD remission'), or with HBI score \>8 ('CD moderate disease') * Capable of providing consent to participate * Access to technology that permits the daily completion of study related activities * Able to receive and have an adult sign for food shipments delivered to a work or home environment. * Negative pregnancy test at screening visit in females of childbearing potential * Able to take oral nutrition and medication intake for 3 months prior to and at time of study enrolment. * 'CD remission' subjects: No change in 'IBD related' medications within 8 weeks prior to normally scheduled appointment with treating gastroenterologist (pre-screening): biologics, immunosuppressants, corticosteroids. Exclusion Criteria: * Short bowel syndrome. * Hospitalized patients * Body mass Index \<19 kg/m or ≥35. * Known clinically significant liver/gallbladder/pancreatic disease/dysfunction * Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, dementia patients. * Uncontrolled Diabetes Type I type II * Known drug abuse. * Known parasitic disease of the digestive system. symptomatic intestinal stricture. * Presence of an ostomy. * Known concurrent malignancy. * Other conditions that would be a contraindication to and of the study diets (e.g. Soy, peanut, wheat, gluten allergy.) or preclude the participant from completing the study * Start of new 'IBD related' medications within 8 weeks prior to enrollment: biologics, immunosuppressants, corticosteroids. * Documented C difficile colitis within four weeks of screening * Well-founded doubt about the patient's cooperation. * Existing pregnancy or lactation. * Current participation in another diet intervention, simultaneous participation in another clinical trial, or participation in any other dietary intervention trial within the last 30 days. * History of \<3 natural bowel movements per week. * Unable to access to technology that permits the daily completion of study related activities. * Currently consuming a soy-based diet

Locations (1)

University Hospitals Digestive Health Institute

Cleveland, Ohio, United States